News

Coronavirus disease 2019 (COVID-19) could cause cold agglutinin disease (CAD), a case report of two patients from France suggests. The cases were described in a letter to the editor of the journal Annals of Hematology. The letter, submitted by researchers from the University…

Japanese patients with cold agglutinin disease (CAD) are almost three times more likely to develop blood clots compared with people without this autoimmune disorder, a study reports. These findings are in agreement with the results for non-Asian populations, according to the researchers. The study, “Demographic characteristics, thromboembolism…

A case report from Michigan suggests that coronavirus disease 2019 (COVID-19) could cause cold agglutinin disease (CAD). Results showed that appropriate treatment, including folic acid and a steroid, lowered inflammation and nearly corrected levels of blood cells. The report, “Cold agglutinin disease and autoimmune hemolytic…

Researchers found a wide range of demographic, clinical, and laboratory characteristics when studying eight patients with cold agglutinin disease (CAD). The findings revealed that treatment with corticosteroids, surgical removal of the spleen, and the use of CellCept (mycophenolate mofetil) — an antirejection medicine given to transplant patients…

The prevalence of cold agglutinin disease (CAD) is four times higher in colder climates than in warmer areas, according to a study from Europe. The findings also showed that a combination of rituximab with bendamustine is a safe and effective therapy for people with CAD. The study,…

Erythropoietin (EPO) treatment safely promotes sustained increases in hemoglobin levels in people with cold agglutinin disease (CAD) and other autoimmune hemolytic anemias (AIHAs), according to a multicenter study in Europe. The data pointed to EPO as a safe and effective treatment for CAD, especially if given within the first…